SCHEMBL9897475

SCHEMBL9897475

CCOC(=O)c1sc(NC(=O)c2cc(Oc3ccc(-c4nnc(C)o4)cc3)cc(OC(C)COC)c2)nc1CO

nearest known ligand 0.49

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GCK P35557 19/20 0.49
KCNH2 Q12809 3/20 0.49
KIFC1 Q9BW19 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9899104 0.93 GCK (0.46) GCKKCNH2
SCHEMBL2734460 0.91 GCK (0.40) GCKKCNH2KIFC1
SCHEMBL2732551 0.88 GCK (0.49) GCKKCNH2
SCHEMBL9899011 0.86 GCK (0.51) GCKKCNH2
SCHEMBL9898354 0.86 GCK (0.55) GCKKCNH2
SCHEMBL9899675 0.84 GCK (0.51) GCKKCNH2
SCHEMBL2725531 0.84 GCK (0.38) GCKKCNH2KIFC1
SCHEMBL9899926 0.84 GCK (0.59) GCKKCNH2
SCHEMBL9898059 0.83 GCK (0.53) GCKKCNH2
SCHEMBL9897078 0.83 GCK (0.53) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450494-B2 Disubstituted benzamide derivatives as glucokinase (GK) activators CADILA HEALTHCARE LIMITED (IN) 2013-05-28 US disclosed
US-20120149704-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149704-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS GCKR, GCK, GK GCK 2/4885KCNH2 256/4885KIFC1 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.